Denise Loring to discuss trends in pharmaceutical patent cases at ACI conference
Denise Loring, a partner in Ropes & Gray's IP Group, will be a featured speaker at the American Conference Institute's ninth annual conference, "Maximizing Pharmaceutical Patent Life Cycles," to be held October 15 - 16 in New York. Loring will serve on a panel that will discuss the topic of identifying judicial trends in pharmaceutical patent cases. Her panel, which will convene at 3:45 pm on October 15, will address the following topics:
The Four Horsemen of the Apocalypse: Delineating the thundering change for patent life cycles triggered by Medimmune, In re Seagate, eBay, KSR and their progeny
Deconstructing the effect, value, and challenges of the covenant not to sue in a post-MedImmune world
What types of covenants have the courts embraced?
What language will trigger rejections by the courts?
Factoring the risk in pursuing a covenant not to sue
Defining the influence of In re Seagate on the concept of ‘reckless disregard’
How does In re Seagate change the need to get a patent opinion?
Scrutinizing the courts’ opinions on the issue of willful infringement in pharma patent cases to project their bearing on present cases
Factoring the eBay decision concerning ‘compulsory licensing’ into your life cycle analysis
Forming a strategy to argue for or defend against an injunction
Examining the different rationales behind preliminary and permanent injunctions
Investigating the decreasing ability to get a preliminary injunction in the initial phase of a patent trial
Adjusting your pharmaceutical patent life cycle strategy to consider the impact of KSR on the obviousness standard
Does KSR eliminate secondary patent protection?
Analyzing court opinions on inequitable conduct to further examine the risks in pharma patent challenges
Determining the latest judicial trends and their consequent impact on a patent life cycle strategy
Forecasting the courts’ future trends in pharma patent cases
What is the Roberts Court’s view of patent cases?